Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Wednesday announced topline data from Phase 1 study of its drug candidate sabirnetug, which is being developed for the treatment of Alzheimer's disease.
The study was designed to compare pharmacokinetics (PK) between subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy volunteers.
Results from the study showed that weekly SC administration of sabirnetug was well-tolerated with systemic exposure supporting further clinical development.
A Phase 2 study of sabirnetug dubbed ALTITUDE-AD in patients with early Alzheimer's disease is underway.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.